Cytogenetics

GC Labs successfully concludes day2 of Medlab Middle East 2024

Retrieved on: 
Tuesday, February 6, 2024

YONGIN, South Korea, Feb. 6, 2024 /PRNewswire/ -- GC Labs, a leading clinical laboratory in South Korea, announced that the company concluded day2 with a successful performance at the Medlab Middle East 2024.

Key Points: 
  • YONGIN, South Korea, Feb. 6, 2024 /PRNewswire/ -- GC Labs, a leading clinical laboratory in South Korea, announced that the company concluded day2 with a successful performance at the Medlab Middle East 2024.
  • GC Labs, specifically, caught visitors' attention by promoting diagnostic test items optimized for the demand and environment of the Middle East market.
  • GC Labs officials said, "GC Labs has built credibility and brand awareness as we have successfully implemented business cooperation with various partners in the Middle East.
  • GC Labs will continue to exhibit at Medlab Middle East 2024 until February 8 at booth Z4.E41.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Retrieved on: 
Friday, January 19, 2024

2024 Symposium will take place virtually from January 22 to 25, 2024.

Key Points: 
  • 2024 Symposium will take place virtually from January 22 to 25, 2024.
  • During these four days, customers will showcase their latest research findings using OGM.
  • Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall.
  • After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey.

Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Retrieved on: 
Wednesday, January 10, 2024

2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease.

Key Points: 
  • 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease.
  • Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall.
  • On day 2, Bionano will unveil a new product expected to advance cytogenetics and structural variant analysis.
  • “At Bionano, we are working to transform the way the world sees the genome,” said Erik Holmlin, PhD, president and chief executive officer of Bionano.

NeoGenomics and ConcertAI Announce Collaboration to Advance Population-Scale, Definitive Hematological Research & Generative AI Solutions at ASH 2023

Retrieved on: 
Monday, January 8, 2024

Hematological malignancies require surveillance of patients over multiple time periods with numerous clinical and diagnostic measures to assess sustained response to treatment or relapse.

Key Points: 
  • Hematological malignancies require surveillance of patients over multiple time periods with numerous clinical and diagnostic measures to assess sustained response to treatment or relapse.
  • Combining ConcertAI's longitudinal clinical data with NeoGenomics' comprehensive biomarkers derived from hundreds of hematological tests we are able to establishe a robust and definitive RWE hematology solution.
  • The collaboration advances molecular and genetic data solutions for the entire drug development lifecycle, from early clinical development to post-approval epidemiological studies.
  • "ConcertAI has spent the last three years with biopharma researchers, medical societies, patient advocacy groups, and academic teams to define requirements for truly definitive, insight-enabling research solutions for hematological malignancies," said Jeff Elton, PhD, CEO of ConcertAI.

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

Retrieved on: 
Thursday, December 14, 2023

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.

Key Points: 
  • SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
  • “I personally believe the importance of OGM for hematological malignancies research cannot be overstated.
  • The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research.
  • “This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward.

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Retrieved on: 
Monday, December 11, 2023

Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Please use this link to participate in the live call; a listen-only version of the webcast is available here .
  • “Leukemic relapse is the leading cause of death in patients undergoing HSCT and prevention of relapse remains a high unmet need.
  • In this trial, the first three patients were high-risk or relapsed AML patients with complex cytogenetics.

Molecular Cytogenetics Market Size, Share & Trends Analysis Report 2023-2030 - A $4.46 billion by 2030, with CAGR of 10.6% from 2023 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023

The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.

Key Points: 
  • The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.
  • The market is expected to expand at a CAGR of 10.6% from 2023 to 2030.
  • Thus, the high incidence of diagnostic testing during the pandemic has fueled the growth of the market for molecular cytogenetics.
  • Moreover, rising strategic initiatives by operating players for technological advancements in cytogenetic tools are projected to propel the market for molecular cytogenetics.

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Retrieved on: 
Sunday, December 10, 2023

“These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.

Key Points: 
  • “These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.
  • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
    This Phase 1b/2 clinical trial evaluated safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and LDAC in patients with ts-AML.
  • This rare, high-risk study population is defined by prior chemotherapy treatment of a previous hematologic disorder, such as myelodysplastic syndrome.
  • Study investigators concluded these data support this low-risk approach to marrow blast reduction and disease control in preparation for HCT.

Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia

Retrieved on: 
Friday, November 17, 2023

The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).

Key Points: 
  • The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).
  • Phase Genomics addresses these legacy challenges with the combination of its OncoTerra technology and Element’s AVITI system for next-generation sequencing, providing a high-resolution alternative for comprehensive, streamlined risk stratification in the research setting.
  • The next-generation cytogenomics all-in-one approach is primed to replace fragmented legacy tests with a single, rapid assay,” said Ivan Liachko, founder and CEO of Phase Genomics.
  • Discover more about next-generation cytogenomics powered by proximity ligation technology in four presentations at AMP23 , or connect with the Phase Genomics team at Booth 810.